346 related articles for article (PubMed ID: 34853355)
1. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.
El Bairi K; Haynes HR; Blackley E; Fineberg S; Shear J; Turner S; de Freitas JR; Sur D; Amendola LC; Gharib M; Kallala A; Arun I; Azmoudeh-Ardalan F; Fujimoto L; Sua LF; Liu SW; Lien HC; Kirtani P; Balancin M; El Attar H; Guleria P; Yang W; Shash E; Chen IC; Bautista V; Do Prado Moura JF; Rapoport BL; Castaneda C; Spengler E; Acosta-Haab G; Frahm I; Sanchez J; Castillo M; Bouchmaa N; Md Zin RR; Shui R; Onyuma T; Yang W; Husain Z; Willard-Gallo K; Coosemans A; Perez EA; Provenzano E; Ericsson PG; Richardet E; Mehrotra R; Sarancone S; Ehinger A; Rimm DL; Bartlett JMS; Viale G; Denkert C; Hida AI; Sotiriou C; Loibl S; Hewitt SM; Badve S; Symmans WF; Kim RS; Pruneri G; Goel S; Francis PA; Inurrigarro G; Yamaguchi R; Garcia-Rivello H; Horlings H; Afqir S; Salgado R; Adams S; Kok M; Dieci MV; Michiels S; Demaria S; Loi S;
NPJ Breast Cancer; 2021 Dec; 7(1):150. PubMed ID: 34853355
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
4. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.
Loi S; Michiels S; Adams S; Loibl S; Budczies J; Denkert C; Salgado R
Ann Oncol; 2021 Oct; 32(10):1236-1244. PubMed ID: 34311075
[TBL] [Abstract][Full Text] [Related]
5. Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer.
Wang H; Ding XH; Liu CL; Xiao Y; Shui RH; Li YP; Chen C; Yang WT; Liu S; Chen CS; Shao ZM; Jiang YZ
J Natl Cancer Inst; 2023 Dec; 115(12):1586-1596. PubMed ID: 37549066
[TBL] [Abstract][Full Text] [Related]
6. Tumor Infiltrating Lymphocytes (TILS) and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications from Pathologist's Perspective.
Angelico G; Broggi G; Tinnirello G; Puzzo L; Vecchio GM; Salvatorelli L; Memeo L; Santoro A; Farina J; Mulé A; Magro G; Caltabiano R
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760449
[TBL] [Abstract][Full Text] [Related]
7. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
8. Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.
Rakaee M; Adib E; Ricciuti B; Sholl LM; Shi W; Alessi JV; Cortellini A; Fulgenzi CAM; Viola P; Pinato DJ; Hashemi S; Bahce I; Houda I; Ulas EB; Radonic T; Väyrynen JP; Richardsen E; Jamaly S; Andersen S; Donnem T; Awad MM; Kwiatkowski DJ
JAMA Oncol; 2023 Jan; 9(1):51-60. PubMed ID: 36394839
[TBL] [Abstract][Full Text] [Related]
9. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.
García-Teijido P; Cabal ML; Fernández IP; Pérez YF
Clin Med Insights Oncol; 2016; 10(Suppl 1):31-9. PubMed ID: 27081325
[TBL] [Abstract][Full Text] [Related]
11. Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions.
Wein L; Savas P; Luen SJ; Virassamy B; Salgado R; Loi S
Front Oncol; 2017; 7():156. PubMed ID: 28824872
[TBL] [Abstract][Full Text] [Related]
12. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
[TBL] [Abstract][Full Text] [Related]
13. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
[TBL] [Abstract][Full Text] [Related]
14. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
15. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating lymphocytes status, programmed death-ligand 1 expression, and clinicopathological features of 41 cases of pure apocrine carcinoma of the breast: a retrospective study based on clinical pathological analysis and different immune statuses.
Xiao X; Jin S; Zhangyang G; Xiao S; Na F; Yue J
Gland Surg; 2022 Jun; 11(6):1037-1046. PubMed ID: 35800740
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
18. Status and prognostic value of immunological biomarkers of breast cancer.
Murazawa C; Hashimoto N; Kuraishi K; Motoyama M; Hashimoto SI; Ikeuchi M; Norimura S; Matsunaga T; Teramoto K; Haba R; Abe N; Yajima T; Kontani K
Oncol Lett; 2023 Apr; 25(4):164. PubMed ID: 36960188
[TBL] [Abstract][Full Text] [Related]
19. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
[TBL] [Abstract][Full Text] [Related]
20. CD204-positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand-1 expression.
Nagano M; Saito K; Kozuka Y; Ichishi M; Yuasa H; Noro A; Imai N; Shibusawa M; Kimoto M; Ishitobi M; Tono Y; Oda H; Ishihara M; Mizuno T; Ogawa T; Katayama N
Oncol Lett; 2021 Jan; 21(1):36. PubMed ID: 33262828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
